<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00539448</url>
  </required_header>
  <id_info>
    <org_study_id>LANTU_L_01578</org_study_id>
    <nct_id>NCT00539448</nct_id>
  </id_info>
  <brief_title>Gulf, Lantus, Apidra Evaluation in Type 1 Diabetics Study</brief_title>
  <acronym>GLANS</acronym>
  <official_title>Phase IV, Open Label, Non-comparative, Multi-center, Study of the Effects of Both Insulin Glargine &amp; Insulin Glulisine in Type I Diabetes Mellitus Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objective :

      To evaluate the efficacy (in terms of change in HbA1c readings starting from baseline then
      after 13 weeks &amp; at the end of the study which will be after 26 weeks) in subjects with type
      I diabetes mellitus.

      Secondary objective :

        -  Recording the average daily dose of both insulin Glulisine &amp; insulin Glargine in type I
           DM.

        -  Recording adverse events.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluating the Glycemic control of the regimen : Change in A1C levels</measure>
    <time_frame>from baseline to study end</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Average daily dose : - For both insulin Glulisine &amp; insulin Glargine. - FBG and PPBG if possible ?</measure>
    <time_frame>from baseline to study end</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">98</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>combination of insulin Glargine &amp; insulin Glulisine as basal bolus regimen</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin glargine</intervention_name>
    <description>in combination with insulin Glulisine as bolus regimen</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin glulisine</intervention_name>
    <description>in combination with insulin Glargine as bolus regimen</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newly diagnosed type I diabetic patients

          -  Type I diabetes treated with basal-bolus regimen including 3 or more injections of
             Regular Human Insulin per day

          -  BMI, 26-40 kg/m2

          -  HbA1c, 7.5%-10%

          -  Median 2Hrs post -prandial more than or equal to 140 mg/dl (more than or equal to 7.8
             mmol/L)

          -  FPG more than or equal to 120 mg/dl (more than or equal to 6.7 mmol/L)

          -  Willingness to accept, and ability to inject insulin Glargine therapy

        Exclusion Criteria:

          -  Pregnancy : The use of LANTUS &amp; APIDRA during pregnancy is not contraindicated.
             However, in the absence of supportive data, Sanofi- Aventis Pharmaceuticals cannot
             specifically recommend the use of Lantus in this patient population

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hisham - MAHMOUD, MD</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-aventis administrative office</name>
      <address>
        <city>Manama</city>
        <country>Bahrain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-aventis administrative office</name>
      <address>
        <city>Kuwait City</city>
        <country>Kuwait</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Doha</city>
        <country>Qatar</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-aventis administrative office</name>
      <address>
        <city>Dubai</city>
        <country>United Arab Emirates</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bahrain</country>
    <country>Kuwait</country>
    <country>Qatar</country>
    <country>United Arab Emirates</country>
  </location_countries>
  <removed_countries>
    <country>Oman</country>
  </removed_countries>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 3, 2007</study_first_submitted>
  <study_first_submitted_qc>October 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2007</study_first_posted>
  <last_update_submitted>September 24, 2009</last_update_submitted>
  <last_update_submitted_qc>September 24, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 25, 2009</last_update_posted>
  <responsible_party>
    <name_title>Medical Affairs Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin glulisine</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

